As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.
10 Analysts have issued a Affimed N.V. forecast:
10 Analysts have issued a Affimed N.V. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1.02 1.02 |
95%
95%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -78 -78 |
41%
41%
|
EBIT (Operating Income) EBIT | -82 -82 |
39%
39%
|
Net Profit | -82 -82 |
41%
41%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Head office | Netherlands |
CEO | Shawn Leland |
Employees | 76 |
Founded | 2000 |
Website | www.affimed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.